Products
Tamtuvetmab Biosimilar Canine Monoclonal Antibody (CD52) for Research
Cat No.: GMP-Bios-ab-548
Pre-Made Tamtuvetmab biosimilar, Canine Whole mAb, Anti-CD52 Antibody: Anti-HE5/CDW52/EDDM5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-548-1mg | 1mg | 3090 |
| GMP-Bios-ab-548-10mg | 10mg | |
| GMP-Bios-ab-548-100mg | 100mg | |
| GMP-Bios-ab-548-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tamtuvetmab biosimilar, Canine Whole mAb, Anti-CD52 Antibody: Anti-HE5/CDW52/EDDM5 therapeutic antibody |
| INN Name | Tamtuvetmab |
| Target | CD52 |
| Format | Canine Whole mAb |
| Derivation | Chimeric (Dog/Rat) |
| Species Reactivity | Canine |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Unknown |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | 1bfo:HG:FE:BA:DC |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Aratana Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Canine T-cell lymphoma |
| Conditions Discontinued | na |
| Development Tech | na |
About target - CD52
1. Protein Vascular endothelial growth factor receptor 2
2. Gene CD52
3. Organism Homo sapiens (Human)
Function
May play a role in carrying and orienting carbohydrate, as well as having a more specific role.
